Table of Contents 2
List of Tables 5
List of Figures 6
Report Guidance 7
GlobalData Clinical Trials Report Coverage 8
Clinical Trials by Region 9
Clinical Trials and Average Enrollment by Country 10
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 13
Top Five Countries Contributing to Clinical Trials in Europe 14
Top Countries Contributing to Clinical Trials in North America 15
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 16
Top Five Countries Contributing to Clinical Trials in Central and South America 17
Clinical Trials by G7 Countries: Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials 18
Clinical Trials by Phase in G7 Countries 20
Clinical Trials in G7 Countries by Trial Status 21
Clinical Trials by E7 Countries: Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials 23
Clinical Trials by Phase in E7 Countries 25
Clinical Trials in E7 Countries by Trial Status 26
Clinical Trials by Phase 28
In Progress Trials by Phase 29
Clinical Trials by Trial Status 30
Clinical Trials by End Point Status 32
Subjects Recruited Over a Period of Time 33
Clinical Trials by Sponsor Type 34
Prominent Sponsors 35
Top Companies Participating in Alzheimer's Disease Therapeutics Clinical Trials 37
Prominent Drugs 39
Latest Clinical Trials News on Alzheimer's Disease 40
Nov 26, 2019: New study by TauRx shows a minimum dose of Hydromethylthionine could slow cognitive decline and brain atrophy in mild-to-moderate Alzheimer's Disease 40
Nov 20, 2019: Athira Pharma to present phase 1 data for NDX-1017 in oral presentation at 2019 clinical trials on Alzheimer's Disease (CTAD) Conference 41
Nov 20, 2019: Cognition Therapeutics to give webcast presentation at Annual Piper Jaffray Healthcare Conference on December 3, 2019 41
Nov 20, 2019: New research demonstrates second direct link between inflammasome activation and Alzheimer's Disease 41
Nov 20, 2019: Tonix Pharmaceuticals completes pre-IND meeting with FDA for TNX-102 SL as a clinical candidate for alcohol use disorder 42
Nov 19, 2019: Oligomerix and Feinstein Institutes publish In Vivo Alzheimer’s Disease treatment data 42
Nov 18, 2019: Karuna Therapeutics announces KarXT met primary endpoint in Phase 2 Clinical Trial of Acute Psychosis in Patients with Schizophrenia 43
Nov 12, 2019: Avanir Pharmaceuticals to continue clinical development of investigational AVP-786 for the treatment of agitation in patients with Alzheimer's Dementia 43
Nov 12, 2019: MGC Pharma receives first Australian Government Grant for CogniCann phase IIb clinical trial, progress towards LSE dual listing 43
Nov 11, 2019: ORYZON to present data on vafidemstat at Upcoming International Conferences 44
Nov 08, 2019: EIP Pharma reports mixed results from neflamapimod Alzheimer’s trial 44
Nov 07, 2019: EIP Pharma announces U.S. FDA grants Fast-Track Designation to Neflamapimod as a treatment for Dementia with Lewy Bodies (DLB) 44
Nov 07, 2019: Inflazome provides update on Inzomelid 45
Nov 07, 2019: Inflazome provides update on Somalix 45
Nov 06, 2019: Alzheon publication defines new path for 2nd generation anti-amyloid drugs for Alzheimer’s Disease, supporting launch of phase 3 study with ALZ-801 oral tablet 45
Nov 04, 2019: Alzheimer's drug Oligomannate gets conditional approval in China 46
Nov 04, 2019: AZTherapies to present at the 25th Annual BIO-EUROPE International Partnering Conference 47
Nov 04, 2019: Biogen to host investor webcasts from clinical trials on Alzheimer’s Disease (CTAD) Congress 47
Oct 30, 2019: Cyclo Therapeutics signs agreement with Worldwide Clinical Trials to conduct Alzheimer’s Disease clinical trial 47
Oct 29, 2019: Unique Alzheimer's Disease Tau vaccine shows great potential in pre-clinical studies 47
Oct 24, 2019: Cassava Sciences clinical results in Alzheimer's selected as late-breaking news at CTAD 2019 48
Oct 23, 2019: Biogen plans to seek FDA approval for Alzheimer’s drug 48
Oct 22, 2019: Oligomerix presents preclinical data on Lead Alzheimer's disease candidate at Neuroscience 2019 49
Oct 21, 2019: INmune Bio announces potentially strong link between obesity and Alzheimer's Disease at the Society for Neuroscience 49th Annual Meeting 49
Oct 17, 2019: ProMIS Neurosciences advances Alzheimers disease program targeting neurotoxic forms of tau 49
Oct 17, 2019: INmune Bio announces presentation of data related to its lead compound XPro1595 at the Society for Neuroscience's Annual Meeting 50
Oct 17, 2019: Arvinas to Present update on Small Molecule to Inhibit Microtubule Associated Protein Tau for Alzheimer's Disease and Progressive Supranuclear Palsy at the 2nd Targeted Protein Degradation Summit 50
Oct 10, 2019: BioXcel Therapeutics provides update on its Schizophrenia drug candidate BXCL501 50
Oct 09, 2019: IntelGenx receives positive DSMB recommendation for Montelukast VersaFilm phase 2a trial 51
Oct 08, 2019: ProMIS Neurosciences identifies novel antibody candidates for multiple system atrophy 51
Oct 04, 2019: Oryzon reveals positive data from anti-aggression drug vafidemstat 52
Oct 03, 2019: ACADIA Pharmaceuticals announces late-breaking oral presentation of the phase 3 HARMONY study of pimavanserin in dementia-related psychosis at the Clinical Trials on Alzheimer’s Disease (CTAD) 2019 Meeting 52
Oct 02, 2019: Athira Pharma Announces Completion of Phase 1b Clinical Trial of NDX-1017 in Alzheimers Patients 53
Sep 30, 2019: Sovateltide (PMZ-1620), an Endothelin-B receptor agonist, has the potential to be a first-in-class neuronal progenitor cell therapeutics 53
Sep 30, 2019: Cognitive Improvement Demonstrated With Xanamem: Actinogen Medical 53
Sep 27, 2019: Anavex Life Sciences presented at the 6th Annual European Rett Syndrome Conference preliminary clinical efficacy data from the U.S. Rett Syndrome Phase 2 ANAVEX2-73 Study 54
Sep 27, 2019: Three new analyses of data expand understanding of the potential role for investigational agent Lemborexant in Insomnia and Irregular Sleep-Wake Rhythm Disorder 55
Sep 24, 2019: Gene therapy shows promise repairing brain tissue damaged by stroke 56
Sep 23, 2019: ORYZON presents new data on vafidemstat 57
Sep 20, 2019: AC Immune receives first milestone payment from Lilly in small molecule Tau Morphomer program 57
Sep 19, 2019: Tetra Therapeutics sees rapid patient recruitment and representative patient diversity in its PICASSO Phase 2 Alzheimer’s Disease Trial 58
Sep 17, 2019: Cassava Sciences to assess Alzheimer’s drug in Phase IIb trial 58
Sep 17, 2019: Theranexus announces inclusion of last subject in its phase IB trial of THN201 59
Sep 16, 2019: Biogen and Eisai discontinue Alzheimer’s trials of BACE inhibitor 59
Sep 16, 2019: Anavex Life Sciences announces preliminary clinical efficacy data of its U.S. phase 2 clinical trial of ANAVEX 2-73 in patients with Rett Syndrome 60
Sep 10, 2019: Neurotrope Alzheimer’s Phase II trial fails to meet endpoints 61
Sep 10, 2019: Cognition Therapeutics’ Founder/CSO to Provide Update on Elayta Clinical Progress at ADDF Alzheimer’s Drug Discovery Conference 61
Sep 09, 2019: Cassava Sciences reports positive phase 2a clinical results in Alzheimer's Patients 61
Sep 09, 2019: New preclinical research suggests Tetra Therapeutics BPN14770 protects against memory loss and neuronal atrophy in Alzheimers disease 62
Sep 09, 2019: Axon announces positive results from phase II ADAMANT trial for AADvac1 in Alzheimers Disease 63
Sep 04, 2019: Cognition Therapeutics to give webcast presentation at 3rd Annual Janney Healthcare Conference on September 9, 2019 64
Clinical Trial Profile Snapshots 65
Appendix 1257
Abbreviations 1257
Definitions 1257
Research Methodology 1258
Secondary Research 1258
About GlobalData 1259
Contact Us 1259
Source 1260
